Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors. Biol Blood Marrow Transplant 2008 Sep;14(9):1064-1071 PMID: 18721770 PMCID: PMC2572684

Pubmed ID

18721770

DOI

10.1016/j.bbmt.2008.07.001

Abstract

This report addresses the concept that permissible HLA mismatching, that is, mismatches that do not generate an allogeneic response, in hematopoietic stem cell transplantation (HCT) can be determined with structural similarity of polymorphic regions. We have applied the triplet version of a structural algorithm called HLAMatchmaker, which considers short sequences involving polymorphic amino acid residues on the molecular surface as key elements of immunogenic epitopes. The triplet matching effect was analyzed in a National Marrow Donor Program dataset consisting of 744 unrelated hematopoietic cell transplantation cases with 1 HLA-A, -B, or -C mismatch and 1690 fully HLA-A, -B, -C, -DR, or -DQ allele matched cases. In multivariate models adjusting for other significant clinical risk factors, the degree of triplet mismatching did not significantly correlate with patient survival, engraftment, or acute graft-versus-host disease (aGVHD). Other structurally based strategies should be pursued to identify permissible HLA mismatches in HCT.

Author List

Duquesnoy R, Spellman S, Haagenson M, Wang T, Horowitz MM, Oudshoorn M

Authors

Mary M. Horowitz MD, MS Center Director, Professor in the Medicine department at Medical College of Wisconsin
Tao Wang PhD Associate Professor in the Institute for Health and Equity department at Medical College of Wisconsin




Scopus

2-s2.0-49449086957   25 Citations

MESH terms used to index this publication - Major topics in bold

Acute Disease
Adolescent
Adult
Aged
Algorithms
Child
Child, Preschool
Databases, Factual
Disease-Free Survival
Donor Selection
Epitopes
Female
Graft Survival
Graft vs Host Disease
Hematologic Neoplasms
Histocompatibility Antigens Class I
Histocompatibility Testing
Humans
Infant
Living Donors
Male
Middle Aged
Retrospective Studies
Risk Factors
Survival Rate
jenkins-FCD Prod-332 f92a19b0ec5e8e1eff783fac390ec127e367c2b5